Cargando…

Role of Selected Circulating Tumor Biomarkers in Patients with Skeletal Metastatic Pancreatic Neuroendocrine Neoplasms

We investigated the diagnostic capacity of selected circulating biomarkers (CBMs) for the early detection of bone metastasis (BMets) in patients with pancreatic neuroendocrine neoplasms (PanNENs). A total of 115 patients with PanNENs and 40 controls were enrolled. We measured the serum levels of fer...

Descripción completa

Detalles Bibliográficos
Autores principales: Rosiek, Violetta, Janas, Ksenia, Witkowska, Magdalena, Kos-Kudła, Beata
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380808/
https://www.ncbi.nlm.nih.gov/pubmed/37510802
http://dx.doi.org/10.3390/jcm12144687
_version_ 1785080286807064576
author Rosiek, Violetta
Janas, Ksenia
Witkowska, Magdalena
Kos-Kudła, Beata
author_facet Rosiek, Violetta
Janas, Ksenia
Witkowska, Magdalena
Kos-Kudła, Beata
author_sort Rosiek, Violetta
collection PubMed
description We investigated the diagnostic capacity of selected circulating biomarkers (CBMs) for the early detection of bone metastasis (BMets) in patients with pancreatic neuroendocrine neoplasms (PanNENs). A total of 115 patients with PanNENs and 40 controls were enrolled. We measured the serum levels of ferritin, cytokeratin 18 (CY18), CA19-9, CA125, AFP, CEA, and beta-2 microglobulin (B2M). A total of eight PanNEN patients developed BMets, and one hundred seven remained BMets-free. We observed a significantly higher level of CA125 and CY18 in BMets patients vs. non-BMets patients (p = 0.01 and p = 0.04, respectively). CA125, CY18, and B2M area under receiver operator characteristic (AUROC) analyses differentiated both patients groups; CA125 area under the curve (AUC) 0.77, p < 0.01; CY18 AUC data were 0.72, p = 0.03, and B2M AUC 0.67, p = 0.02. On the basis of CBM metrics in both subgroups, we reached a sensitivity/specificity for CA125 of 75/76%; for CY18 of 75/69%, for B2M of 100/50%, for CA125, and the CY18 combination of 93/90%, respectively. According to current results, CA125 and CY18 seem to have the potential capacity as fair biomarkers for BMets detection, despite the small number of cases. Further studies are warranted in the larger PanNEN patient group.
format Online
Article
Text
id pubmed-10380808
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-103808082023-07-29 Role of Selected Circulating Tumor Biomarkers in Patients with Skeletal Metastatic Pancreatic Neuroendocrine Neoplasms Rosiek, Violetta Janas, Ksenia Witkowska, Magdalena Kos-Kudła, Beata J Clin Med Article We investigated the diagnostic capacity of selected circulating biomarkers (CBMs) for the early detection of bone metastasis (BMets) in patients with pancreatic neuroendocrine neoplasms (PanNENs). A total of 115 patients with PanNENs and 40 controls were enrolled. We measured the serum levels of ferritin, cytokeratin 18 (CY18), CA19-9, CA125, AFP, CEA, and beta-2 microglobulin (B2M). A total of eight PanNEN patients developed BMets, and one hundred seven remained BMets-free. We observed a significantly higher level of CA125 and CY18 in BMets patients vs. non-BMets patients (p = 0.01 and p = 0.04, respectively). CA125, CY18, and B2M area under receiver operator characteristic (AUROC) analyses differentiated both patients groups; CA125 area under the curve (AUC) 0.77, p < 0.01; CY18 AUC data were 0.72, p = 0.03, and B2M AUC 0.67, p = 0.02. On the basis of CBM metrics in both subgroups, we reached a sensitivity/specificity for CA125 of 75/76%; for CY18 of 75/69%, for B2M of 100/50%, for CA125, and the CY18 combination of 93/90%, respectively. According to current results, CA125 and CY18 seem to have the potential capacity as fair biomarkers for BMets detection, despite the small number of cases. Further studies are warranted in the larger PanNEN patient group. MDPI 2023-07-14 /pmc/articles/PMC10380808/ /pubmed/37510802 http://dx.doi.org/10.3390/jcm12144687 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Rosiek, Violetta
Janas, Ksenia
Witkowska, Magdalena
Kos-Kudła, Beata
Role of Selected Circulating Tumor Biomarkers in Patients with Skeletal Metastatic Pancreatic Neuroendocrine Neoplasms
title Role of Selected Circulating Tumor Biomarkers in Patients with Skeletal Metastatic Pancreatic Neuroendocrine Neoplasms
title_full Role of Selected Circulating Tumor Biomarkers in Patients with Skeletal Metastatic Pancreatic Neuroendocrine Neoplasms
title_fullStr Role of Selected Circulating Tumor Biomarkers in Patients with Skeletal Metastatic Pancreatic Neuroendocrine Neoplasms
title_full_unstemmed Role of Selected Circulating Tumor Biomarkers in Patients with Skeletal Metastatic Pancreatic Neuroendocrine Neoplasms
title_short Role of Selected Circulating Tumor Biomarkers in Patients with Skeletal Metastatic Pancreatic Neuroendocrine Neoplasms
title_sort role of selected circulating tumor biomarkers in patients with skeletal metastatic pancreatic neuroendocrine neoplasms
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10380808/
https://www.ncbi.nlm.nih.gov/pubmed/37510802
http://dx.doi.org/10.3390/jcm12144687
work_keys_str_mv AT rosiekvioletta roleofselectedcirculatingtumorbiomarkersinpatientswithskeletalmetastaticpancreaticneuroendocrineneoplasms
AT janasksenia roleofselectedcirculatingtumorbiomarkersinpatientswithskeletalmetastaticpancreaticneuroendocrineneoplasms
AT witkowskamagdalena roleofselectedcirculatingtumorbiomarkersinpatientswithskeletalmetastaticpancreaticneuroendocrineneoplasms
AT koskudłabeata roleofselectedcirculatingtumorbiomarkersinpatientswithskeletalmetastaticpancreaticneuroendocrineneoplasms